tradingkey.logo

enVVeno Medical Corp

NVNO

4.840USD

-0.030-0.62%
Horarios del mercado ETCotizaciones retrasadas 15 min
93.16MCap. mercado
PérdidaP/E TTM

enVVeno Medical Corp

4.840

-0.030-0.62%
Más Datos de enVVeno Medical Corp Compañía
enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.
Información de la empresa
Símbolo de cotizaciónNVNO
Nombre de la empresaenVVeno Medical Corp
Fecha de salida a bolsaMay 31, 2018
Director ejecutivoMr. Robert A. Berman
Número de empleados37
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 31
Dirección70 Doppler
CiudadIRVINE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92618
Teléfono19492612900
Sitio Webhttps://envveno.com/
Símbolo de cotizaciónNVNO
Fecha de salida a bolsaMay 31, 2018
Director ejecutivoMr. Robert A. Berman
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
102.34K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
10.36K
-7.17%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
102.34K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
10.36K
-7.17%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Kingdon Capital Management, L.L.C.
4.46%
The Vanguard Group, Inc.
3.12%
Nantahala Capital Management, LLC
3.09%
UBS O'Connor LLC
1.54%
Westside Investment Management, LLC
1.35%
Other
86.44%
Accionistas
Accionistas
Proporción
Kingdon Capital Management, L.L.C.
4.46%
The Vanguard Group, Inc.
3.12%
Nantahala Capital Management, LLC
3.09%
UBS O'Connor LLC
1.54%
Westside Investment Management, LLC
1.35%
Other
86.44%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
10.14%
Investment Advisor
6.99%
Investment Advisor/Hedge Fund
2.62%
Research Firm
1.20%
Individual Investor
0.92%
Venture Capital
0.17%
Private Equity
0.14%
Other
77.80%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
72
3.82M
21.80%
-3.16M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
2023Q2
55
2.71M
28.61%
-1.36M
2023Q1
54
2.76M
29.13%
-1.37M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Kingdon Capital Management, L.L.C.
859.26K
4.9%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
600.91K
3.43%
+11.77K
+2.00%
Mar 31, 2025
Nantahala Capital Management, LLC
594.66K
3.39%
-2.26K
-0.38%
Mar 31, 2025
UBS O'Connor LLC
296.03K
1.69%
--
--
Mar 31, 2025
Westside Investment Management, LLC
259.05K
1.48%
+54.02K
+26.35%
Mar 31, 2025
Geode Capital Management, L.L.C.
197.30K
1.13%
+15.56K
+8.56%
Mar 31, 2025
J.P. Morgan Securities LLC
194.21K
1.11%
-75.83K
-28.08%
Mar 31, 2025
Altium Capital Management LP
123.26K
0.7%
-186.74K
-60.24%
Mar 31, 2025
Duhay (Francis)
102.34K
0.58%
--
--
Feb 26, 2025
Dauntless Investment Group, LLC
70.85K
0.4%
+70.85K
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proporción0.02%
Dimensional US Core Equity 1 ETF
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Fecha
Tipo
Relación
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
KeyAI